Optimizing the Value of CAR T-Cell Therapy: Managed Care Considerations From Recent Clinical Findings

Optimizing the Value of CAR T-Cell Therapy: Managed Care Considerations From Recent Clinical Findings

Faculty
Larry W. Buie, PharmD, BCOP, FASHP
Manager, Clinical Pharmacy
Program Director, PGY2 Oncology Residency
Memorial Sloan Kettering Cancer Center
New York, New York

Rebecca Borgert, PharmD, BCOP
Senior Director
Oncology Clinical Strategy and Innovation
Magellan Rx Management
Gainesville, Florida

Medical Writing and Editorial Support

Julianna Merten, PharmD, BCPS, BCOP
Medical Writer
Chimeric Medical Communications, LLC
Saint Ansgar, Iowa

Jane de Lartigue, PhD
Medical Writer
Newberry, Florida
 
Program Description
A number of factors have contributed to the widespread use of chimeric antigen receptor-modified (CAR) T-cell therapy in the treatment of B-cell malignancies. While the cost of CAR T-cell therapy can be more than twice that of standard oncology care, long-term benefits suggest a strong potential for their cost-effectiveness and improved gains in overall survival for patients. These considerations have spurred discussions about earlier initiation of CAR T-cell therapy in treatment algorithms for patients with aggressive B-cell malignancies. With emerging data on indications for therapy and financial regulations for CAR T-cell therapy, managed care professionals will be challenged by increased volume of patients receiving CAR T-cell therapies and evolving payment and reimbursement schema. To facilitate patient access to these treatments, the multidisciplinary healthcare team must standardize processes for the integration of CAR T-cell therapies into the treatment landscape of patients with B-cell malignancies and determine optimal payment modalities to improve patient outcomes.


Target audience: Managed care pharmacists
Type of activity: Application
Release date: August 16, 2021
Expiration date: February 16, 2022
Time to complete activity: 2 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Explore the rationale for CAR T-cell therapy in hematologic malignancies.
• Analyze the evolving landscape of CAR T-cell therapy and the most recent data for new and emerging treatments.
• Investigate strategies being developed to improve outcomes and mitigate costs associated with CAR T-cell therapy.

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-294-H01-P. The activity is available for CE credit through February 16, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the online article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Rebecca Borgert, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Seagen
• Advisory Board: Pfizer, Sanofi
• Spouse — Employee: Melinta Therapeutics
   

Larry W. Buie, PharmD, BCOP, FASHP, has no relevant financial relationships with commercial interests to disclose.

Medical Writing and Editorial Support

Julianna Merten, PharmD, BCPS, BCOP, and Jane de Lartigue, PhD, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Kelly McCormick; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy
According to the disclosure policy of The American Journal of Managed Care® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care®, Pharmacy Times Continuing Education™, or the companies that provided commercial support for this CE activity.

Signed disclosures are on file at the office of The American Journal of Managed Care®, Cranbury, New Jersey.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms